Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won't be taking the drug forward itself. Enter ...

By highlighting two examples of kinase signaling (Aurora kinases and phosphatidylinositol-3-OH kinases) in which such readouts are inconsistent, we argue that the phenotypes need not necessarily ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation ...